Establishment of a spontaneous metastasis tumor model for human ErbB-2 vaccine
- PMID: 28178631
- DOI: 10.1016/j.biopha.2017.01.099
Establishment of a spontaneous metastasis tumor model for human ErbB-2 vaccine
Abstract
Human ErbB-2 (Her-2) is a critical target for cancer immunotherapy, and its over-expression can promote cancer migration and invasion. Compared with passive antibody therapy, vaccination treatment is more effective in the prevention of cancer recurrence. BALB-neuT mouse is a spontaneous metastasis tumor model used for testing the anti-tumor metastatic effect of rat ErbB-2 (neu) vaccine. However, no spontaneous metastasis tumor model used for evaluating Her-2 vaccine has been developed. In the current study, we attempted to use murine melanoma cell lines to establish a stable spontaneous metastasis tumor model for Her-2 vaccines. We developed Her-2-positive B16F10 and B16BL6 cell lines expressing similar Her-2 levels as the typical human tumor cell line SKBR-3. Results showed that Her-2-positive B16BL6, rather than B16F10, cell line could effectively and spontaneously transfer to the lungs approximately 28days after the removal of primary tumors because it has stronger adhesion and invasion capacities. A stable spontaneous metastasis model was developed through in vivo screening of Her-2-positvie B16BL6 cells twice. This model was successfully applied in the analysis of the anti-metastatic efficacy of a tumor vaccine based on heat shock protein. Thus, we first established a spontaneous metastasis model that stably expresses Her-2 at similar levels as human cancers. This model can be used to evaluate the anti-metastatic efficacy of Her-2 vaccine.
Keywords: Cancer; Her-2; Spontaneous metastasis; Tumor model; Vaccine.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16. Cancer Res. 2010. PMID: 20233867
-
Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.Cell Immunol. 2006 Apr;240(2):96-106. doi: 10.1016/j.cellimm.2006.07.002. Epub 2006 Aug 22. Cell Immunol. 2006. PMID: 16930573
-
Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.Breast Cancer Res Treat. 2007 Nov;106(1):29-38. doi: 10.1007/s10549-006-9469-4. Epub 2007 Jan 3. Breast Cancer Res Treat. 2007. PMID: 17203384
-
Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Breast Cancer Res Treat. 2013 Feb;138(1):1-12. doi: 10.1007/s10549-013-2410-8. Epub 2013 Jan 23. Breast Cancer Res Treat. 2013. PMID: 23340862 Review.
-
HER-2/neu as a target for cancer vaccines.Immunotherapy. 2010 Mar;2(2):213-26. doi: 10.2217/imt.09.89. Immunotherapy. 2010. PMID: 20635929 Review.
Cited by
-
Advances in Immunotherapy for Melanoma: A Comprehensive Review.Mediators Inflamm. 2017;2017:3264217. doi: 10.1155/2017/3264217. Epub 2017 Aug 1. Mediators Inflamm. 2017. PMID: 28848246 Free PMC article. Review.
-
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.Front Immunol. 2023 Apr 19;14:1181014. doi: 10.3389/fimmu.2023.1181014. eCollection 2023. Front Immunol. 2023. PMID: 37153626 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous